NEWARK, DE — The global CCR6 antagonists market is entering a high-growth phase, expanding from USD 1.0 billion in 2026 to USD 4.0 billion by 2036, registering a CAGR of 12.0%, according to Future Market Insights (FMI). Growth is being driven by increasing adoption of targeted immunotherapies, rising prevalence of autoimmune and inflammatory diseases, and expanding clinical trial...

Saudi Arabia’s Pharmaceutical Industry to Reach USD 17.7 Billion by 2035, Fueled by Prescription Drug Demand and Healthcare Expansion NEWARK, DE — The pharmaceutical industry in Saudi Arabia is poised for steady growth, expected to increase from USD 10.6 billion in 2025 to USD 17.7 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.2%, according to...

NEWARK, DE — The global gastroesophageal reflux disease (GERD) device market is witnessing steady growth, expected to expand from USD 1.3 billion in 2026 to USD 2.0 billion by 2036, registering a CAGR of 3.9%, according to Future Market Insights (FMI). Market expansion is being driven by rising prevalence of digestive disorders, increasing obesity rates, and growing adoption of...

NEWARK, DE — The global platelet rich plasma (PRP) market is poised for robust growth, expanding from USD 537.8 million in 2026 to USD 1,409.6 million by 2036, reflecting a CAGR of 10.1%, according to Future Market Insights (FMI). The market is benefiting from rising adoption of regenerative medicine solutions, minimally invasive therapeutic approaches, and growing demand in...

NEWARK, DE — The global research antibodies market is set to witness substantial growth, expanding from USD 6.05 billion in 2026 to USD 13.19 billion by 2036, reflecting a CAGR of 8.10%, according to Future Market Insights (FMI). Increasing investments in biomedical research, rising demand for reproducible experimental workflows, and the growing adoption of multiplexed assays across...

NEWARK, DE — The global repurposed human immunosuppressants market is set for steady expansion, growing from USD 748.78 million in 2026 to USD 1,129.88 million by 2036, registering a CAGR of 4.20%, according to Future Market Insights (FMI). The market is gaining traction as established immunosuppressant drugs are increasingly repurposed for non-transplant indications such as...